Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human ErbB4 /HER4 Protein, Fc Tag, 100µg  

Recombinant human ErbB4 /HER4 Protein, Fc Tag, 100µg

Recombinant Human ErbB4 /HER4 Protein, Gln 26 - Pro 651 was produced in human 293 cells (HEK293), Fc Tag

Synonym
recombinant, human, protein HER4, ErbB4, MGC138404, p180erbB4

More details

ER4-H5251-100

Availability: within 7 days

338,00 €

Background
Receptor tyrosine-protein kinase erbB-4 (ErbB4), also known as Her4, is a single-pass type I transmembrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. ErbB4 is expressed in normal skeletal muscle, heart, pituitary, brain and several breast carcinomas. ERBB4 contains multiple furin-like cysteine rich domains, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is activated by neuregulins-2 and -3, heparin-binding EGF-like growth factor and betacellulin. Ligand binding induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment. ErbB4 appears to play important roles in neuronal development, development of the heart and cancer. ERBB4 has been shown to interact with: DLG4[1-2], NRG1, STAT5A,[3-4] and YAP1.[5] Mutations in this gene have been associated with cancer. Other single-nucleotide polymorphisms and a risk haplotype have been linked to schizophrenia.[6]

Source
Recombinant Human ErbB4, Fc Tag (ER4-H5251) is expressed from human 293 cells (HEK293). It contains AA Gln 26 - Pro 651 (Accession # Q15303-1).
Predicted N-terminus: Gln 26

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 96.0 kDa. The protein migrates as 90-106 kDa and 116-120 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Transcriptomic Signature and Growth Factor Regulation of Castration-Tolerant Prostate Luminal Progenitor Cells
Baures, Puig Lombardi, Di Martino et al
Cancers (Basel) (2022) 14 (15)
(2) "Design, synthesis and neurite outgrowth activity of novel ganglioside GM1 derivatives by remodeling of the fatty acid moiety
Chen, Jin, Huang et al
Eur J Med Chem (2022) 241, 114636
(3) "MiRNA sequencing of Embryonic Myogenesis in Chengkou Mountain Chicken
Shi, Li, Liu et al
BMC Genomics (2022) 23 (1), 571
Showing 1-3 of 2219 papers.